The patent is co-owned by AnaCardio AB and Helsinn Healthcare SA and provides protection in the United States until June 2, 2042, plus potential patent term extensions.

“This newly issued U.S. patent significantly strengthens the intellectual property protection for AC01 and reinforces the long-term exclusivity we have built around our lead candidate in the world’s largest pharmaceutical market. Together with our broader patent portfolio, it creates a strong and layered IP position supporting AC01 well into the 2040s. We believe AC01 has the potential to become a truly transformative therapy for patients with heart failure and reduced ejection fraction, addressing one of the most significant unmet medical needs in cardiovascular medicine,” says Patrik Strömberg, AnaCardio CEO.